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Curative resection for left-sided pancreatic malignancy
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Abstract
Background. Surgical technique in pancreatic cancer has seen significant development, but much of the knowledge refers to
pancreatic head carcinoma. Reports on the management of tumours of the body and tail have been less frequent. Current
knowledge teaches that adenocarcinomas of the body and tail of the pancreas have a worse prognosis. The aim of this study is
to report the short- and long-term outcome in 20 patients with left-sided pancreatic malignancy, where ‘resection for cure’
was done. Patients and methods. Retrospective study of demographic data, symptomatology, diagnostic methods, operative
management, pathology report, postoperative morbidity and mortality. Results. Postoperative complications were seen in
40% of patients. One patient died on day 5 from sepsis with multiple organ failure. Other complications were intra-abdominal
bleeding, bleeding from the gastroentero-anastomosis, postoperative jaundice, pleural exudate, wound dehiscence and intra-
abdominal abscess. The patients with ductal adenocarcinoma had a median survival of 14 months and a 5-year survival of
17%. The median survival for the whole group of patients was 17 months and the 5-year survival was 23%. One patient with
malignant insulinoma and two patients with adenocarcinoma had a survival exceeding 5 years (98, 174 and 183 months,
respectively). Discussion. Selected patients with left-sided pancreatic adenocarcinoma may be operated on with results
similar to pancreaticoduodenectomy (Whipple procedure) for cancer of the pancreatic head regarding postoperative
morbidity and mortality as well as long-term survival. Thus, although left-sided pancreatic cancer generally appears at a more
advanced stage, it seems true that treatment results are similar if radical excision can be achieved.
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Introduction
Surgical technique in pancreatic cancer has seen
significant development. Thirty years ago, pancreati-
coduodenectomy was associated with a postoperative
mortality of 2030%, including reports from large
institutions, whereas the acceptable standard today is
a few percent [17]. Although long-term survival may
not have improved to the same extent, development
and sophistication of imaging modalities such as
sonography, computed tomography (CT) and mag-
netic resonance (MR) scanning have made diagnosis
and especially accurate staging easier, which means
that malignancies limited to the pancreas may be
selected for surgery. Several reports indicate improved
survival after pancreaticoduodenectomy with curative
intent, with median and 5-year survival figures in the
range of 1120 months and 725%, respectively
[1,37].
However, much of the knowledge gained refers to
pancreatic head carcinoma, and reports on the
management of tumours of the body and tail have
been less frequent. Current knowledge teaches that
adenocarcinomas of the body and tail of the pancreas
have a worse prognosis. As all surgeons caring for
these patients know, all too often left-sided carcino-
mas do not present until there is overgrowth on
adjacent organs, large vessels and nerve tissue, usually
signalled by the ominous sign of pain radiating to the
back. Although some reports indicate that results of
surgery for left-sided malignancy are not improving
[810], other authors have found decreasing post-
operative mortality and improved survival figures
[1113]. The aim of this study is to report the short-
and long-term outcome after attempted curative
surgery for malignant tumours of the body and tail
of the pancreas. It extends a previous study from our
department [14].
Patients and methods
From 1977 through 2004, 300 patients had pancrea-
tic resection of a pancreatic malignancy, and 20 of
them (8 men, 12 women) were operated on because of
a malignant tumour of the body and/or tail of the
pancreas. The median age was 63 years, range 4975
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years. The individual patient charts were reviewed
regarding demographic data, symptomatology, diag-
nostic methods, operative management, pathology
report, postoperative morbidity and mortality. Our
standard has been to attempt surgery only when a
curative resection seemed possible, and resection was
abstained from in the presence of peritoneal implants,
encasement of superior mesenteric or coeliac artery,
or distant lymph node or organ metastases. Tumours
were staged according to the TNM classification.
Adjuvant therapy was not used in this time period.
Follow-up was done in our outpatient clinic, with
clinical control together with ultrasound examination
of the abdomen every third month for the first year
after surgery, and thereafter twice a year until death or
September 2004. Data are usually presented as
median value with range or interquartile range
(IQR); 5-year survival was estimated by Kaplan-
Meier analysis.
Results
The most common symptoms of left-sided pancreatic
carcinoma were abdominal pain (16/20) and weight
loss (16/20). A few patients had jaundice (5/20).
Ultrasound was positive in 15 of 17 (88%) attempted
cases, CT scanning in 9/9 (100%) patients. ERCP
(endoscopic retrograde cholangiopancreatography)
showed pancreatic duct stenosis in six of six patients,
and PTCA (percutaneous transluminal coronary
angioplasty) showed stenosis in four of five patients
with jaundice. A preoperative cytologic diagnosis of
malignancy was available in 10 of the 20 patients.
Fourteen patients had a distal (left-sided) pancrea-
tic resection and six patients a total pancreatectomy,
and to the standard procedure was added resection of
the stomach, the renal capsule, the portal vein and the
renal vein in eight patients (Table I). The median
operating time was 360 min. Median estimated blood
loss was 2500 ml, and patients received 1400 ml
(median) packed red blood cells. The mean tumour
size was 5.5 cm. Microscopically radical resection
(R0) was achieved in 17 patients, and macroscopic
(R1) radicality in another 3 patients. The tumours
were classified as adenocarcinoma (16 patients),
malignant non-hormone-producing endocrine cancer
(2 patients) and mucinous cystadenocarcinoma (2
patients). Histopathological data including tumour
stage are shown in Table I.
Postoperative complications were seen in 8/20
(40%) patients. One patient developed a severe post-
operative sepsis with multiple organ failure and death
occurred on day 5. Other complications were intra-
abdominal bleeding (1/20), bleeding from the gastro-
entero-anastomosis (1/20), postoperative jaundice (1/
20), pleural exudate (2/20), wound dehiscence (2/20)
and intra-abdominal abscess (2/20).
In the group of patients where a resection of the
portal vein was performed, a major complication
occurred in three patients (60%). The only post-
operative death was noted in this group. The median
survival for the whole group of patients was 17
months (range 0183; IQR 1144;), and the 5-year
survival was 23% (see Figure 1). Considering only the
patients with ductal adenocarcinoma, the median
survival was 14 months (range 0183; IQR 1244)
and the 5-year survival was 17% (Table I).
Discussion
A lot of pessimism has been associated with malig-
nancies of the body and tail of the pancreas, as
signified by the fact that it was possible until recently
Table I. Characteristics of surgical procedures and tumour pathology.
Surgical
procedure
No. of
patients
Total pancreatectomy 6
with resection of portal vein 3
Distal (left)
hemipancreatectomy
14
with resection of stomach 1
with resection of renal capsule 1
with resection of portal vein 2
with resection of renal vein 1
Pathological features
Adenocarcinoma 16
high differentiation 2
moderate differentiation 7
low differentiation 7
Endocrine cancer 2
Mucinous
cystadenocarcinoma
2
Tumour stage IA 1
IB 3
IIA 2
IIB 7
III 7
Radicality microscopic (R0) 17
macroscopic (R1) 3
Figure 1. Survival rate after resection for adenocarcinoma of the
body and tail of the pancreas (n/16).
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to publish single-case reports of long-term survival
after resection of a left-sided pancreatic malignancy
[1517]. In this study from a tertiary referral centre,
we report 20 patients where ‘resection for cure’ of a
left-sided pancreatic malignancy was done, currently
the only chance of long-term survival. The whole
group of patients had a median survival of 17 months,
and a 5-year survival of 23%, whereas the subgroup of
ductal adenocarcinoma of body and tail of the
pancreas had an over-all median survival of 14
months, and a projected 5-year survival of 17%.
One patient with malignant insulinoma, and two
patients with adenocarcinoma had a survival exceed-
ing 5 years (98, 174 and 183 months, respectively).
Several authors report poor survival after resection for
left-sided carcinoma (Table II). However, our figures
compare well with some newer studies [5,12,13,18].
Thus, results with left-sided resection appear similar
to those seen after pancreaticoduodenectomy (Whip-
ple procedure) for cancer of the pancreatic head [1,3
7]. Although, the data in Table II are scarce, they may
support the importance of achieving an R0 resection,
as is the case with pancreaticoduodenectomy [5,19].
In the present series, we achieved an R0 resection in
81% of patients with adenocarcinoma, and in all
patients with endocrine cancer and cystadenocarci-
noma.
Our patients represent a highly selected subset of
patients, as many of them attended at least one or two
peripheral clinics/hospitals before being admitted to
our department. Thus, we lack data on the total
number of left-sided pancreatic cancer, and the ‘true
resection rate’ cannot be estimated. In previous
studies, the resection rate was 250% [8,9,2024].
It seems most likely that this wide span to a large
extent may reflect different referral patterns and
modes of selection. In a comprehensive population
study from the UK a resection rate of approximately
2% for carcinoma of the body and tail of the pancreas
was found, while it was 6% for pancreatic head
carcinoma, thus attesting to the clinical experience
that left-sided tumours are less often resectable [10].
The majority of patients with left-sided pancreatic
cancer have metastatic disease at the time of diagnosis
[8,25]. Locally advanced disease is also common. In
this study, seven (35%) of the 20 patients were
classified as stage III, which agrees with previous
studies, where local overgrowth was noted in 3040%
of the resected patients [23,26,27]. One-third of our
patients were subjected to either resection of major
veins (6/20) or adjacent organs (2/20). This compares
well with an earlier study, in which the authors
performed extended pancreatic resection in 22 of 57
(39%) patients [13]. Pancreatic resection is contra-
indicated when there are metastases to peritoneum,
distant lymph nodes, the liver and other distant
organs, as well as in the presence of overgrowth on
the central arteries. We believe that resection of the
portal vein may be permitted, if an R0 resection is
possible and it can be done with acceptable morbidity
and mortality Although not uncontroversial, the same
argument has been raised in favour of extended
pancreaticoduodenectomy for advanced pancreatic
head carcinoma [26,27]. Our experience suggests,
however, that it is used judiciously, and abstained
from if technically difficult (i.e. broad encasement),
and done only if an R0 resection is possible. Cystic
neoplasms and endocrine cancers seem to have a
Table II. Results with resection of left-sided pancreatic carcinoma.
Authors
[ref.]
No.of
resections
Mortality
(%)
Complications
(%)
No. of
adenocarcinomas
Rate of
radical resection R0
(%)
Median
survival
(months)
5-year
survival
rate (%)
Nakase et al. [20] 90 10  90   1*
Matsuno & Sato [21] 7 0?  7  8.4 0*
Miyata et al. [22] 13 15.3 23 13  6 0*
Dalton et al. [23] 44 2 27 26 73  8*
Nordback et al. [24] 9 0 44  7 11*
Johnson et al. [8] 13 0  13   0*
Bramhall et al. [10] 34 40  34   0*
Wade et al. [34] 29 21 44 29   
Brennan et al. [31] 34 0 23 34   9*
Fabre et al. [9] 128 9 32 128  9.1$ 0
Nakao et al. [33] 30 7  30 57  10%
Sperti et al. [18] 24 8 25 24 67  12.5*
Lillemoe et al. [11] 225 0.9 31 43   
Adam et al. [32] 41 2.5 41 10   
Falconi et al. [12] 25 0  25 60 17.6 10%
Shoup et al. [13] 57 0  57 72 15.9 
This study 20 5 40 16 81 14 17%
*Crude 5-year survival.
$Subgroup (n/79) without metastases.
%Actuarial 5-year survival.
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better prognosis in this study as well as in previous
reports [2830], and these histiotypes may thus
warrant more aggressive surgery.
Postoperative complications were common, and
occurred in 8/20 (40%) patients, which is similar to
previously reported complication rates in the range of
2344% (Table II); a level comparable to that seen
with pancreaticoduodenectomy [17]. Despite the
extensive and complication-prone surgery used in
some of the patients, we experienced a reasonable
5% hospital mortality. This figure is comparable to
recent results with pancreaticoduodenectomy [1,3
7]. Although a low mortality after left-sided pancrea-
tic resection was also shown in some previous studies
[1113,3133], other reports found a higher mortal-
ity [10,22,23,34]. Several explanations may be en-
tertained. Pre- and intraoperative assessment of which
patients to proceed with radical surgery is probably of
utmost importance, thus abstaining from hazardous
surgery in patients where there is little hope of cure.
The experience and skill of the surgeon is another
important factor; in this study one of the authors
(F.B.) performed or assisted a majority of the opera-
tions. However, recent studies underline that the
yearly number of pancreatic procedures at the unit
may be as important as the case-load per surgeon.
Our department is one of five referral centres for
pancreatic surgery in Denmark [35]. Conceivably, a
dedicated team of experienced surgeons, anaesthesiol-
ogists, nurses, etc., may have a great impact on the
perioperative management of the patient, not least the
timely and appropriate treatment of complications. In
fact, the importance of the surgical unit has been
considered a strong argument for centralization of
pancreatic surgery [4,36].
In conclusion, selected patients with left-sided
pancreatic adenocarcinoma may be operated on with
results similar to pancreaticoduodenectomy for cancer
of the pancreatic head regarding postoperative mor-
bidity and mortality as well as long-term survival.
Thus, although left-sided pancreatic cancer generally
appears at a more advanced stage, it seems true that
treatment results are similar when compared ‘stage-
to-stage’ [22]. As with pancreatic head carcinoma,
however, it is equally obvious that refinement of
surgery will not solve the problem. Most resected
patients will still die from their disease [13]. Future
hope may reside in earlier diagnosis and the develop-
ment of efficient adjuvant regimens.
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